532321 Stock Overview
Engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Zydus Lifesciences Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹972.60 |
52 Week High | ₹1,323.90 |
52 Week Low | ₹602.10 |
Beta | 0.42 |
11 Month Change | -7.74% |
3 Month Change | -25.27% |
1 Year Change | 58.73% |
33 Year Change | 97.64% |
5 Year Change | 315.29% |
Change since IPO | 15,018.30% |
Recent News & Updates
Recent updates
Shareholder Returns
532321 | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | -2.9% | 3.0% | 1.6% |
1Y | 58.7% | 54.1% | 36.9% |
Return vs Industry: 532321 exceeded the Indian Pharmaceuticals industry which returned 54.1% over the past year.
Return vs Market: 532321 exceeded the Indian Market which returned 36.9% over the past year.
Price Volatility
532321 volatility | |
---|---|
532321 Average Weekly Movement | 3.6% |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 6.2% |
10% most volatile stocks in IN Market | 9.3% |
10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 532321 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 532321's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1952 | 26,921 | Sharvil Patel | zyduslife.com |
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases.
Zydus Lifesciences Limited Fundamentals Summary
532321 fundamental statistics | |
---|---|
Market cap | ₹979.32b |
Earnings (TTM) | ₹41.69b |
Revenue (TTM) | ₹206.15b |
23.5x
P/E Ratio4.8x
P/S RatioIs 532321 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
532321 income statement (TTM) | |
---|---|
Revenue | ₹206.15b |
Cost of Revenue | ₹63.05b |
Gross Profit | ₹143.10b |
Other Expenses | ₹101.41b |
Earnings | ₹41.69b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 12, 2024
Earnings per share (EPS) | 41.43 |
Gross Margin | 69.41% |
Net Profit Margin | 20.22% |
Debt/Equity Ratio | 3.7% |
How did 532321 perform over the long term?
See historical performance and comparison